Category Archives: Public Policy

Latest From Public Policy

Counterfeiting: White House IP Czar Victoria Espinel on working with corporations

Victoria Espinel

White house IP Czar Victoria Espinel spoke at BIO’s 2011 International Convention in a session titled Counterfeiting: How corporations and government can work together.  She told the audience that when entering her new assignment she was surprised to find out that counterfeiting was a large problem in the United States and not just abroad. The Administration has increased enforcement in counterfeit medicines as seizures of health related counterfeits have gone up 97% from last year.  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Docs at BIO: Patent Litigation Tactics and Strategies for Biosimilars

One of the highlights of the afternoon sessions at the BIO International Convention was a seminar appropriately entitled “A Brave New World: Patent Litigation Tactics and Strategies for Biosimilars,” where an experienced panel of patent attorneys presented their interpretation of the new biosimilars pathway of the Biologics Price Competition and Innovation Act and speculated on some of the potential issues that will arise once the statute is put into practice.  From Patent Docs.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Biotech Patenting and Tech Transfer at 2011 BIO International Convention

BIO11_ConvLogo_L_RGB

The Biotech Patenting and Tech Transfer track has a lot to offer 2011 BIO International Convention Attendees.  High level speakers include White House Intellectual Property Enforcement Coordinator Victoria Espinel, European Patent Office Director of Biotechnology Sjoerd Hoekstra, retired Chief Judge of the U.S. Court of Appeals for the Federal Circuit Paul Michel, and former Solicitors General Seth Waxman and Paul Clement to name a few.                 I am particularly excited about the breadth of the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , ,

House Patent Reform Bill, HR 1249, still has the Administration’s and BIO’s support

patent reform june 22 2011

The White House, Office of Management and Budget, Office of Science and Technology Policy, and the United States Patent and Trademark Office have come out in support of HR 1249 and the Manager’s Amendment to the bill.  The only caveat mentioned is that “final legislative action [should] ensure that the US Patent and Trademark Office’s (USPTO’s) fee collections are made fully available to support the nation’s patent and trademark system.” BIO also has come out in Read More >

Patently BIOtech  |  3 Comments  |  Email This Post
Tags: , , , , , ,

‘Gene Patents’ Stifle Research?

'Gene Patents' Stifle Research?

The Federal Trade Commission has noted that “concern previously centered on the belief that biotechnology patent protection was too strong” and “would actually obstruct commercialization on new products, thereby hindering follow-on innovation.  This problem has yet to materialize.  The reasons for this are numerous and are often straightforward matters of basic economics. In addition to licensing being widely available, researchers make use of a variety [of] strategies to develop working solutions to the problem of Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,